Lau L, Tai D, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. Journal of Pediatric Hematology/Oncology 2004, 26:227-232.

Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, Qu W, Jimeno J, Bernstein M, Baruchel S. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clinical Cancer Research 2005, 11 (2 Pt 1):672-677.

Lau L, Baruchel S: Can Canada sustain paediatric phase I trials? A national survey of cancer relapse in children. Canadian Journal of Clinical Pharmacology 2005, 12(3) e229-e239.

Lau L, Krafchik B, Trebo M, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatric Blood and Cancer 2006, 46(1):66-71.

Lau L, Hargrave D, Bartels U, Esquembre C, Bouffet E. Childhood brain tumor information on the internet in the Chinese language. Child's Nervous System 2006, 22(4):346-351.

Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, Irwin MS. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 2007, 26: 1920-1931.

Lau L, Stuurman K, Weitzman S. Skeletal Langerhan cell histiocytosis in children: Permanent consequences and health-related quality of life in long-term survivors. Pediatric Blood and Cancer 2008, 50(3): 607-612.

Lau LMS, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008, 27: 997-1003

Lau LMS, Wolter JK, Lau JT, Cheng LS, Smith KM, Hansford LM, Zhang L, Baruchel S, Robinson F, Irwin MS. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 2009, 28: 2024-2033.

Lau LMS and Irwin MS. Molecular Pathogenesis of Neuroblastomas. In: Mehta MP, Chang SM, Vogelbaum MA, Guha A, editors. Principles and Practices of Neuro-Oncology: A Multidisciplinary Approach. New York: Demos Medical Publishing. (in press)